DIABETES drug Jardiance
(empagliflozin) from Boehringer
Ingelheim and Eli Lilly is to be
studied for the treatment of people
with chronic heart failure (CHF).
Two concurrent clinical trials will
commence within 12 months and
recruit people with CHF both with
and without type 2 diabetes.
The research follows previous
Jardiance trials which showed a
reduction in cardiovascular risk.The above article was sent to subscribers in Pharmacy Daily's issue from 20 Apr 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Apr 16
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.